References
- Gilliam LA, St Clair DK. Chemotherapy-induced weakness and fatigue in skeletal muscle: the role of oxidative stress. Antioxid Redox Signal. 2011;15(9):2543–63. doi:https://doi.org/10.1089/ars.2011.3965
- Hydock DS, Lien CY, Jensen BT, Schneider CM, Hayward R. Characterization of the effect of in vivo doxorubicin treatment on skeletal muscle function in the rat. Anticancer Res. 2011;31:2023–8.
- Schwartz AL. Daily fatigue patterns and effect of exercise in women with breast cancer. Cancer Pract. 2000;8(1):16–24. doi:https://doi.org/10.1046/j.1523-5394.2000.81003.x
- Sawyer DB, Peng X, Chen B, Pentassuglia L, Lim CC. Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection? Prog Cardiovasc Dis. 2010;53(2):105–13. doi:https://doi.org/10.1016/j.pcad.2010.06.007
- Gewirtz DA. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol. 1999;57(7):727–41. doi:https://doi.org/10.1016/s0006-2952(98)00307-4
- Tokarska-Schlattner M, Zaugg M, Zuppinger C, Wallimann T, Schlattner U. New insights into doxorubicin-induced cardiotoxicity: the critical role of cellular energetics. J Mol Cell Cardiol. 2006;41(3):389–405. doi:https://doi.org/10.1016/j.yjmcc.2006.06.009
- Santacruz L, Darrabie MD, Mantilla JG, Mishra R, Feger BJ, Jacobs DO. Creatine supplementation reduces doxorubicin-induced cardiomyocellular injury. Cardiovasc Toxicol. 2015;15(2):180–8. doi:https://doi.org/10.1007/s12012-014-9283-x
- Tokarska-Schlattner M, Dolder M, Gerber I, Speer O, Wallimann T, Schlattner U. Reduced creatine-stimulated respiration in doxorubicin challenged mitochondria: particular sensitivity of the heart. Biochim Biophys Acta. 2007;1767(11):1276–84. doi:https://doi.org/10.1016/j.bbabio.2007.08.006
- Gupta A, Rohlfsen C, Leppo MK, Chacko VP, Wang Y, Steenbergen C, Weiss RG. Creatine kinase-overexpression improves myocardial energetics, contractile dysfunction and survival in murine doxorubicin cardiotoxicity. PLoS One. 2013;8(10):e74675. doi: https://doi.org/10.1371/journal.pone.0074675
- Marques-Aleixo I, Santos-Alves E, Oliveira PJ, Moreira PI, Magalhães J, Ascensão A. The beneficial role of exercise in mitigating doxorubicin-induced Mitochondrionopathy. Biochim Biophys Acta Rev Cancer. 2018;1869(2):189–99. doi:https://doi.org/10.1016/j.bbcan.2018.01.002
- Gilliam LAA, Fisher-Wellman KH, Lin C-T, Maples JM, Cathey BL, Neufer PD. The anticancer agent doxorubicin disrupts mitochondrial energy metabolism and redox balance in skeletal muscle. Free Radic Biol Med. 2013;65:988–96. doi:https://doi.org/10.1016/j.freeradbiomed.2013.08.191
- Gilliam LAA, Moylan JS, Patterson EW, Smith JD, Wilson AS, Rabbani Z, Reid MB. Doxorubicin acts via mitochondrial ROS to stimulate catabolism in C2C12 myotubes. Am J Physiol Cell Physiol. 2012;302(1):C195–202. doi:https://doi.org/10.1152/ajpcell.00217.2011
- Meredith AM, Dass CR. Increasing role of the cancer chemotherapeutic doxorubicin in cellular metabolism. J Pharm Pharmacol. 2016;68(6):729–41. doi:https://doi.org/10.1111/jphp.12539
- Mizutani H, Tada-Oikawa S, Hiraku Y, Kojima M, Kawanishi S. Mechanism of apoptosis induced by doxorubicin through the generation of hydrogen peroxide. Life Sci. 2005;76(13):1439–53. doi:https://doi.org/10.1016/j.lfs.2004.05.040
- DeAtley SM, Aksenov MY, Aksenova MV, Jordan B, Carney JM, Butterfield DA. Adriamycin-induced changes of creatine kinase activity in vivo and in cardiomyocyte culture. Toxicology. 1999;134(1):51–62. doi:https://doi.org/10.1016/s0300-483x(99)00039-6
- Persky AM, Brazeau GA. Clinical pharmacology of the dietary supplement creatine monohydrate. Pharmacol Rev. 2001;53(2):161–76.
- Klein AM, Ferrante RJ. The neuroprotective role of creatine. Subcell Biochem. 2007;46:205–43. doi:https://doi.org/10.1007/978-1-4020-6486-9_11
- Adhihetty PJ, Beal MF. Creatine and its potential therapeutic value for targeting cellular energy impairment in neurodegenerative diseases. Neuromolecular Med. 2008;10(4):275–90. doi:https://doi.org/10.1007/s12017-008-8053-y
- Wyss M, Kaddurah-Daouk R. Creatine and creatinine metabolism. Physiol Rev. 2000;80(3):1107–213. doi:https://doi.org/10.1152/physrev.2000.80.3.1107
- Kley RA, Tarnopolsky MA, Vorgerd M. Creatine for treating muscle disorders. Cochrane Database Syst Rev. 2013;(6):CD004760. doi:https://doi.org/10.1002/14651858.CD004760.pub4
- Sestili P, Martinelli C, Bravi G, Piccoli G, Curci R, Battistelli M, Falcieri E, Agostini D, Gioacchini AM, Stocchi V, et al. Creatine supplementation affords cytoprotection in oxidatively injured cultured mammalian cells via direct antioxidant activity. Free Radic Biol Med. 2006;40(5):837–49.:doi:https://doi.org/10.1016/j.freeradbiomed.2005.10.035
- Sestili P, Martinelli C, Colombo E, Barbieri E, Potenza L, Sartini S, Fimognari C. Creatine as an antioxidant. Amino Acids. 2011;40(5):1385–96. doi:https://doi.org/10.1007/s00726-011-0875-5
- Ichikawa Y, Ghanefar M, Bayeva M, Wu R, Khechaduri A, Naga Prasad SV, Mutharasan RK, Naik TJ, Ardehali H. Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation. J Clin Invest. 2014;124(2):617–30. doi:https://doi.org/10.1172/JCI72931
- Gorini S, De Angelis A, Berrino L, Malara N, Rosano G, Ferraro E. Chemotherapeutic drugs and mitochondrial dysfunction: focus on doxorubicin, trastuzumab, and sunitinib. Oxid Med Cell Longev. 2018;2018:7582730. doi:https://doi.org/10.1155/2018/7582730
- Chaudhari U, Ellis JK, Wagh V, Nemade H, Hescheler J, Keun HC, Sachinidis A. Metabolite signatures of doxorubicin induced toxicity in human induced pluripotent stem cell-derived cardiomyocytes. Amino Acids. 2017;49(12):1955–63. doi:https://doi.org/10.1007/s00726-017-2419-0
- Supriya R, Tam BT, Pei XM, Lai CW, Chan LW, Yung BY, Siu PM. Doxorubicin induces inflammatory modulation and metabolic dysregulation in diabetic skeletal muscle. Front Physiol. 2016;7:323. doi:https://doi.org/10.3389/fphys.2016.00323
- Darrabie MD, Arciniegas AJL, Mantilla JG, Mishra R, Vera MP, Santacruz L, Jacobs DO. Exposing cardiomyocytes to subclinical concentrations of doxorubicin rapidly reduces their creatine transport. Am J Physiol Heart Circ Physiol. 2012;303(5):H539–48. doi:https://doi.org/10.1152/ajpheart.00108.2012
- van Norren K, van Helvoort A, Argilés JM, van Tuijl S, Arts K, Gorselink M, Laviano A, Kegler D, Haagsman HP, van der Beek EM, et al. Direct effects of doxorubicin on skeletal muscle contribute to fatigue. Br J Cancer. 2009;100(2):311–4.:doi:https://doi.org/10.1038/sj.bjc.6604858
- Smuder AJ, Kavazis AN, Min K, Powers SK. Exercise protects against doxorubicin-induced oxidative stress and proteolysis in skeletal muscle. J Appl Physiol. 2011;110(4):935–42. doi:https://doi.org/10.1152/japplphysiol.00677.2010
- Zervou S, Whittington HJ, Ostrowski PJ, Cao F, Tyler J, Lake HA, Neubauer S, Lygate CA. Increasing creatine kinase activity protects against hypoxia/reoxygenation injury but not against anthracycline toxicity in vitro. PLoS One. 2017;12(8):e0182994. doi: https://doi.org/10.1371/journal.pone.0182994
- Matthews NE, Adams MA, Maxwell LR, Gofton TE, Graham CH. Nitric oxide-mediated regulation of chemosensitivity in cancer cells. J Natl Cancer Inst. 2001;93(24):1879–85. doi: https://doi.org/10.1093/jnci/93.24.1879
- Elbl L, Vasova I, Tomaskova I, Jedlicka F, Kral Z, Navratil M, Smardova L, Wagnerova B, Vorlicek J. Cardiopulmonary exercise testing in the evaluation of functional capacity after treatment of lymphomas in adults. Leuk Lymphoma. 2006;47(5):843–51. doi: https://doi.org/10.1080/10428190500402559
- Bonifati DM, Ori C, Rossi CR, Caira S, Fanin M, Angelini C. Neuromuscular damage after hyperthermic isolated limb perfusion in patients with melanoma or sarcoma treated with chemotherapeutic agents. Cancer Chemother Pharmacol. 2000;46(6):517–22. doi:https://doi.org/10.1007/s002800000175
- Takemura G, Fujiwara H. Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management. Prog Cardiovasc Dis. 2007;49(5):330–52. doi:https://doi.org/10.1016/j.pcad.2006.10.002
- Campbell TL, Quadrilatero J. Data on skeletal muscle apoptosis, autophagy, and morphology in mice treated with doxorubicin. Data Brief. 2016;7:786–93. doi:https://doi.org/10.1016/j.dib.2016.03.009
- Kalyanaraman B, Joseph J, Kalivendi S, Wang S, Konorev E, Kotamraju S. Doxorubicin-induced apoptosis: implications in cardiotoxicity. Mol Cell Biochem. 2002;234-235(1-2):119–24.
- Baird MF, Graham SM, Baker JS, Bickerstaff GF. Creatine-kinase- and exercise-related muscle damage implications for muscle performance and recovery. J Nutr Metab. 2012;2012:960363 doi:https://doi.org/10.1155/2012/960363
- Lawler JM, Barnes WS, Wu G, Song W, Demaree S. Direct antioxidant properties of creatine. Biochem Biophys Res Commun. 2002;290(1):47–52. doi:https://doi.org/10.1006/bbrc.2001.6164
- Meyer LE, Machado LB, Santiago APSA, da-Silva WS, De Felice FG, Holub O, Oliveira MF, Galina A. Mitochondrial creatine kinase activity prevents reactive oxygen species generation: antioxidant role of mitochondrial kinase-dependent ADP re-cycling activity. J Biol Chem. 2006;281(49):37361–71. doi:https://doi.org/10.1074/jbc.M604123200
- Rambo LM, Ribeiro LR, Oliveira MS, Furian AF, Lima FD, Souza MA, Silva LFA, Retamoso LT, Corte CLD, Puntel GO, et al. Additive anticonvulsant effects of creatine supplementation and physical exercise against pentylenetetrazol-induced seizures. Neurochem Int. 2009;55(5):333–40.:doi:https://doi.org/10.1016/j.neuint.2009.04.007
- Matthews RT, Yang L, Jenkins BG, Ferrante RJ, Rosen BR, Kaddurah-Daouk R, Beal MF. Neuroprotective effects of creatine and cyclocreatine in animal models of Huntington’s disease. J Neurosci. 1998;18(1):156–63.